Welcome

Zero-Dose Costing Meeting

29-30 April, 2024
Gavi ZD costing use cases

- To inform HSS portfolio funding guidelines by understanding the cost of interventions, particularly packages of interventions (and integration), cost-effectiveness, incremental cost per zero-dose child reached, and by setting (fragile/conflict, rural, urban)
- To inform FPP planning and budgeting
- To strengthen country financing and budgeting systems, including subnational immunization commitment and financing
- To inform analyses of contribution of Gavi’s investments to strategy goals and deaths averted
- To inform trade off decisions for the design of the 6.0 strategy and to inform advocacy for funding during the replenishment
- A better understanding of costs to users and hidden costs useful to inform and address demand side barriers and advocacy
Costing in recent pro-equity evidence briefs

Available at: https://zdlh.gavi.org/resources/evidence-map

• Synthesized information about cost and cost-effectiveness for 12 priority pro-equity interventions in LMIC

• Findings
  • Limited information on costs and cost-effectiveness, and difficult to compare across studies
  • “User incentives” was considered a ‘proven’ intervention with good information on costing, although with wide variation
  • “Provider incentives” also had more information on costing, although with varied quality. Overall intervention considered ‘inconclusive’.

➢ Better guidance, more agreement on how to improve comparability, and visibility on costing methods needed
Thank you